Literature DB >> 24832159

The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater.

Daphne C Ang1, Jinru Shia, Laura H Tang, Nora Katabi, David S Klimstra.   

Abstract

Histologic classification of ampullary carcinomas into intestinal, pancreatobiliary, or other subtypes is easily achievable in some cases but difficult in others. Immunohistochemical (IHC) stains may allow distinction between the subtypes; however, their added value to routine hematoxylin and eosin (H&E) evaluation has not been systematically evaluated. Inconsistent histologic subtyping has hampered current clinical research and therapeutic trials. In this study, a consecutive series of 105 ampullary carcinomas was subtyped first by H&E evaluation and then by the evaluation of an IHC panel composed of CK7, CK20, CDX2, MUC1, and MUC2, and the added value of IHC was analyzed. By H&E, a consensus diagnosis, defined as concordant subtyping among at least 3 of the 4 independent study pathologists, was achieved in 81 of the 105 (77%) cases. There was excellent agreement for poorly differentiated and mucinous subtypes (κ=0.72 and 0.89, respectively) but only good agreement for intestinal and pancreatobiliary subtypes (κ=0.57 and 0.48, respectively) and poor agreement for mixed subtype (κ=0.09). By IHC, CK7 showed no informative value (being positive in ≥70% of the cases in both intestinal and pancreatobiliary subtypes), whereas a subtyping schema incorporating the combination staining patterns of CK20, CDX2, MUC1, and MUC2 did. By this schema, "intestinal subtype" was defined as having (1) positive staining for CK20 or CDX2 or MUC2 and negative staining for MUC1, or (2) positive staining for CK20, CDX2, and MUC2, irrespective of the MUC1 result; and "pancreatobiliary subtype" was defined as having positive staining for MUC1 and negative staining for CDX2 and MUC2, irrespective of CK20 results. Cases not fitting one of these 3 categories were regarded as "ambiguous" immunohistochemically. By combining this schema with H&E evaluation, 97 of the 105 cases (92%) could be classified into either intestinal or pancreatobiliary subtype. In particular, immunophenotyping allowed categorization of 75% of poorly differentiated adenocarcinomas and 69% of cases with mixed histologic features as either intestinal or pancreatobiliary subtype. Most mucinous adenocarcinomas (88%) were clearly intestinal subtype by IHC. Thus, our IHC schema enhanced the subtyping of ampullary carcinoma and, in combination with H&E evaluation, allowed a dichotomous classification in 92% of the cases. Should further independent studies reaffirm our findings, this schema may serve as a valuable tool in both diagnostic and research settings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24832159     DOI: 10.1097/PAS.0000000000000230

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  34 in total

1.  Immunohistochemical Predictors for Intestinal and Pancreatobiliary Types of Adenocarcinoma of The Ampulla of Vater.

Authors:  João Paulo Lemos da Silveira Santos; Carla Jorge Machado; Eduardo Paulino Junior; João Bernardo Sancio Rocha Rodrigues; Paula Teixeira Vidigal; Vivian Resende
Journal:  J Gastrointest Surg       Date:  2018-05-07       Impact factor: 3.452

2.  Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.

Authors:  Anca Nastase; Jin Yao Teo; Hong Lee Heng; Cedric Chuan Young Ng; Swe Swe Myint; Vikneswari Rajasegaran; Jia Liang Loh; Ser Yee Lee; London Lucien Ooi; Alexander Yaw Fui Chung; Pierce Kah Hoe Chow; Peng Chung Cheow; Wei Keat Wan; Rafy Azhar; Avery Khoo; Sam Xin Xiu; Syed Muhammad Fahmy Alkaff; Ioana Cutcutache; Jing Quan Lim; Choon Kiat Ong; Vlad Herlea; Simona Dima; Dan G Duda; Bin Tean Teh; Irinel Popescu; Tony Kiat Hon Lim
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

3.  Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.

Authors:  Yue Xue; Alessandro Vanoli; Serdar Balci; Michelle M Reid; Burcu Saka; Pelin Bagci; Bahar Memis; Hyejeong Choi; Nobuyike Ohike; Takuma Tajiri; Takashi Muraki; Brian Quigley; Bassel F El-Rayes; Walid Shaib; David Kooby; Juan Sarmiento; Shishir K Maithel; Jessica H Knight; Michael Goodman; Alyssa M Krasinskas; Volkan Adsay
Journal:  Mod Pathol       Date:  2016-10-14       Impact factor: 7.842

4.  Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2).

Authors:  Jaclyn F Hechtman; Weiguo Liu; Justyna Sadowska; Lisa Zhen; Laetitia Borsu; Maria E Arcila; Helen H Won; Ronak H Shah; Michael F Berger; Efsevia Vakiani; Jinru Shia; David S Klimstra
Journal:  Mod Pathol       Date:  2015-05-15       Impact factor: 7.842

5.  Clinical, morphologic, and immunophenotypic characteristics of ampullary carcinomas with an emphasis on SMAD4 expression.

Authors:  Ahmad Alkhasawneh; Lizette Vila Duckworth; Thomas J George; Neelam V Desai; Alex J Sommerfeld; Xiaomin Lu; Tania Zuluaga Toro
Journal:  J Gastrointest Oncol       Date:  2016-12

6.  Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases.

Authors:  Michelle D Reid; Serdar Balci; Nobuyuki Ohike; Yue Xue; Grace E Kim; Takuma Tajiri; Bahar Memis; Ipek Coban; Anil Dolgun; Alyssa M Krasinskas; Olca Basturk; David A Kooby; Juan M Sarmiento; Shishir K Maithel; Bassel F El-Rayes; Volkan Adsay
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

7.  Clinicopathological Study of Carcinoma of the Ampulla of Vater with Special Reference to MUC1, MUC2 and MUC5AC Expression.

Authors:  Maithili Mandar Kulkarni; Siddhi Gaurish Sinai Khandeparkar; Avinash R Joshi; Aniket Kakade; Lokesh Fegade; Ketan Narkhede
Journal:  J Clin Diagn Res       Date:  2017-05-01

8.  Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: A case report.

Authors:  Nicole Max; Alexander Rothe; Cord Langner
Journal:  Mol Clin Oncol       Date:  2016-04-14

9.  Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma.

Authors:  Shinichi Yachida; Laura D Wood; Masami Suzuki; Erina Takai; Yasushi Totoki; Mamoru Kato; Claudio Luchini; Yasuhito Arai; Hiromi Nakamura; Natsuko Hama; Asmaa Elzawahry; Fumie Hosoda; Tomoki Shirota; Nobuhiko Morimoto; Kunio Hori; Jun Funazaki; Hikaru Tanaka; Chigusa Morizane; Takuji Okusaka; Satoshi Nara; Kazuaki Shimada; Nobuyoshi Hiraoka; Hirokazu Taniguchi; Ryota Higuchi; Minoru Oshima; Keiichi Okano; Seiko Hirono; Masamichi Mizuma; Koji Arihiro; Masakazu Yamamoto; Michiaki Unno; Hiroki Yamaue; Matthew J Weiss; Christopher L Wolfgang; Toru Furukawa; Hitoshi Nakagama; Bert Vogelstein; Tohru Kiyono; Ralph H Hruban; Tatsuhiro Shibata
Journal:  Cancer Cell       Date:  2016-01-21       Impact factor: 31.743

10.  T-complex-associated-testis-expressed 3 (TCTE3) is a novel marker for pancreatobiliary carcinomas.

Authors:  Chaohui Lisa Zhao; Yiang Hui; Li Juan Wang; Kara Lombardo; Dongfang Yang; Shamlal Mangray; Evgeny Yakirevich; Ali Amin; Chiung-Kuei Huang; Shaolei Lu
Journal:  Hum Pathol       Date:  2017-10-24       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.